Functional mutation of multiple solvent-exposed loops in the Ecballium elaterium trypsin inhibitor-II cystine knot miniprotein

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Kimura, Richard H ^a   Jones, Douglas S ^b   Jiang, Lei ^a   Miao, Zheng ^a   Cheng, Zhen ^a   Cochran, Jennifer R ^b  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHAVBETA5 INTEGRIN; COOPER 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID KNOTTIN 3 4A CU 64; ECBALLIUM ELATERIUM TRYPSIN INHIBITOR 2 CYSTEINE KNOT MINIPROTEIN; EPITOPE; MOLECULAR SCAFFOLD; MUTANT PROTEIN; POLYPEPTIDE; RADIOPHARMACEUTICAL AGENT; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 5; VITRONECTIN; VITRONECTIN RECEPTOR; PEPTIDE FRAGMENT; SOLVENT; TRYPSIN INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CHILD; CONTROLLED STUDY; CUCUMBER; CYSTINE KNOT MOTIF; DISULFIDE BOND; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG STABILITY; DRUG TARGETING; DRUG TUMOR LEVEL; ECBALLIUM ELATERIUM; EXTRACELLULAR MATRIX; FEMALE; GLIOBLASTOMA; HUMAN; IC 50; INDUCED MUTATION; ISOTOPE LABELING; MOLECULAR WEIGHT; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN STABILITY; PROTEIN SYNTHESIS INHIBITION; RECEPTOR AFFINITY; TUMOR XENOGRAFT; URINARY EXCRETION; AMINO ACID SEQUENCE; ANIMAL; CELL ADHESION; CELL STRAIN K 562; CHEMICAL STRUCTURE; CHEMISTRY; DRUG SCREENING; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; MUTATION; NUDE MOUSE; PHYSIOLOGY; PROTEIN BINDING; PROTEIN FOLDING; PROTEIN TERTIARY STRUCTURE; SEQUENCE HOMOLOGY; SITE DIRECTED MUTAGENESIS; SYNTHESIS; TUMOR CELL CULTURE;

ECBALLIUM ELATERIUM;

AMINO ACID SEQUENCE; ANIMALS; CELL ADHESION; CUCURBITACEAE; CYSTINE KNOT MOTIFS; FEMALE; HUMANS; K562 CELLS; MICE; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; MUTATION; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN FOLDING; PROTEIN STRUCTURE, TERTIARY; SEQUENCE HOMOLOGY, AMINO ACID; SOLVENTS; TRYPSIN INHIBITORS; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79951996425     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016112     Document Type: Article

References (62)

1. Pallaghy PK, Nielsen KJ, Craik DJ, Norton RS, (1994) A common structural motif incorporating a cystine knot and a triple-stranded beta-sheet in toxic and inhibitory polypeptides. Protein Sci 3: 1833-1839.
2. Chiche L, Heitz A, Gelly JC, Gracy J, Chau PT, et al. (2004) Squash inhibitors: from structural motifs to macrocyclic knottins. Curr Protein Pept Sci 5: 341-349.
3. Kolmar H, (2009) Biological diversity and therapeutic potential of natural and engineered cystine knot miniproteins. Curr Opin Pharmacol 9: 608-614.
4. Craik DJ, Daly NL, Waine C, (2001) The cystine knot motif in toxins and implications for drug design. Toxicon 39: 43-60.
5. Kolmar H, (2008) Alternative binding proteins: biological activity and therapeutic potential of cystine-knot miniproteins. FEBS J 275: 2684-2690.
6. Christmann A, Walter K, Wentzel A, Kratzner R, Kolmar H, (1999) The cystine knot of a squash-type protease inhibitor as a structural scaffold for Escherichia coli cell surface display of conformationally constrained peptides. Protein Eng 12: 797-806.
7. Hilpert K, Wessner H, Schneider-Mergener J, Welfle K, Misselwitz R, et al. (2003) Design and characterization of a hybrid miniprotein that specifically inhibits porcine pancreatic elastase. J Biol Chem 278: 24986-24993.
8. Kimura RH, Levin AM, Cochran FV, Cochran JR, (2009) Engineered cystine knot peptides that bind αvβ3, αvβ5, and α5β1 integrins with low-nanomolar affinity. Proteins 77: 359-369.
9. Krause S, Schmoldt HU, Wentzel A, Ballmaier M, Friedrich K, et al. (2007) Grafting of thrombopoietin-mimetic peptides into cystine knot miniproteins yields high-affinity thrombopoietin antagonists and agonists. FEBS J 274: 86-95.
10. Reiss S, Sieber M, Oberle V, Wentzel A, Spangenberg P, et al. (2006) Inhibition of platelet aggregation by grafting RGD and KGD sequences on the structural scaffold of small disulfide-rich proteins. Platelets 17: 153-157.
11. Silverman AP, Kariolis MS, Cochran JR, (2011) Cystine-knot peptides engineered with specificities for αiibβ3 or αiibβ3 and αvβ3 integrins are potent inhibitors of platelet aggregation. J Mol Recognit 24: 127-135.
12. Silverman AP, Levin AM, Lahti JL, Cochran JR, (2009) Engineered cystine-knot peptides that bind αvβ3 integrin with antibody-like affinities. J Mol Biol 385: 1064-1075.
13. Heitz A, Avrutina O, Le-Nguyen D, Diederichsen U, Hernandez JF, et al. (2008) Knottin cyclization: impact on structure and dynamics. BMC Struct Biol 8: 54.
14. Favel A, Mattras H, Coletti-Previero MA, Zwilling R, Robinson EA, et al. (1989) Protease inhibitors from Ecballium elaterium seeds. Int J Pept Protein Res 33: 202-208.
15. Hynes RO, (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25.
16. Cai W, Niu G, Chen X, (2008) Imaging of integrins as biomarkers for tumor angiogenesis. Curr Pharm Des 14: 2943-2973.
17. Haubner R, (2006) αvβ3-integrin imaging: a new approach to characterise angiogenesis? Eur J Nucl Med Mol Imaging 33 (Suppl 1): 54-63.
18. Alghisi GC, Ruegg C, (2006) Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium 13: 113-135.
19. Stupack DG, Cheresh DA, (2004) Integrins and angiogenesis. Curr Top Dev Biol 64: 207-238.
20. Brooks PC, Clark RA, Cheresh DA, (1994) Requirement of vascular integrin αvβ3 for angiogenesis. Science 264: 569-571.
21. Kim S, Bell K, Mousa SA, Varner JA, (2000) Regulation of angiogenesis in vivo by ligation of integrin α5β1 with the central cell-binding domain of fibronectin. Am J Pathol 156: 1345-1362.
22. Miao Z, Ren G, Liu H, Kimura RH, Jiang L, et al. (2009) An engineered knottin peptide labeled with 18F for PET imaging of integrin expression. Bioconjug Chem 20: 2342-2347.
23. Kimura RH, Cheng Z, Gambhir SS, Cochran JR, (2009) Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. Cancer Res 69: 2435-2442.
24. Lahti JL, Silverman AP, Cochran JR, (2009) Interrogating and predicting tolerated sequence diversity in protein folds: application to E. elaterium trypsin inhibitor-II cystine-knot miniprotein. PLoS Comput Biol 5: e1000499.
25. Ruoslahti E, (1996) RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 12: 697-715.
26. Zhang X, Xiong Z, Wu Y, Cai W, Tseng JR, et al. (2006) Quantitative PET imaging of tumor integrin αvβ3 expression with 18F-FRGD2. J Nucl Med 47: 113-121.
27. Pfaff M, McLane MA, Beviglia L, Niewiarowski S, Timpl R, (1994) Comparison of disintegrins with limited variation in the RGD loop in their binding to purified integrins αiibβ3, αvβ3 and α5β1 and in cell adhesion inhibition. Cell Adhes Commun 2: 491-501.
28. Bruning A, Runnebaum IB, (2003) CAR is a cell-cell adhesion protein in human cancer cells and is expressionally modulated by dexamethasone, TNFalpha, and TGFbeta. Gene Ther 10: 198-205.
29. Blystone SD, Graham IL, Lindberg FP, Brown EJ, (1994) Integrin αvβ3 differentally regulates adhesive and phagocytic functions of the fibronectin receptor α5β1. J Cell Biol 127: 1129-1137.
30. Tucker GC, (2006) Integrins: molecular targets in cancer therapy. Curr Oncol Rep 8: 96-103.
31. Wentzel A, Christmann A, Kratzner R, Kolmar H, (1999) Sequence requirements of the GPNG beta-turn of the Ecballium elaterium trypsin inhibitor II explored by combinatorial library screening. J Biol Chem 274: 21037-21043.
32. Jiang L, Kimura RH, Miao Z, Silverman AP, Ren G, et al. (2010) Evaluation of a 64Cu-labeled cystine-knot peptide based on agouti-related protein for PET of tumors expressing αvβ3 integrin. J Nucl Med 51: 251-258.
33. Kimura RH, Miao Z, Cheng Z, Gambhir SS, Cochran JR, (2010) A dual-labeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects. Bioconjug Chem 21: 436-444.
34. Miao Z, Levi J, Cheng Z, (2010) Protein scaffold-based molecular probes for cancer molecular imaging. Amino Acids epub Feb 12.
35. Willmann JK, Kimura RH, Deshpande N, Lutz AM, Cochran JR, et al. (2010) Targeted contrast-enhanced ultrasound imaging of tumor angiogenesis with contrast microbubbles conjugated to integrin-binding knottin peptides. J Nucl Med 51: 433-440.
36. Kolmar H, (2010) Engineered cystine-knot miniproteins for diagnostic applications. Expert Rev Mol Diagn 10: 361-368.
37. Garcia Boy R, Mier W, Nothelfer EM, Altmann A, Eisenhut M, et al. (2010) Sunflower trypsin inhibitor 1 derivatives as molecular scaffolds for the development of novel peptidic radiopharmaceuticals. Mol Imaging Biol 12: 377-385.
38. Nielsen CH, Kimura RH, Withofs N, Tran PT, Miao Z, et al. (2010) PET Imaging of Tumor Neovascularization in a Transgenic Mouse Model with a Novel 64Cu-DOTA-Knottin Peptide. Cancer Res 70: 9022-9030.
39. Haubner R, Finsinger D, Kessler H, (1997) Stereoisomeric peptide libaries and peptidomimetics for designing selective inhibitors of the αvβ3 integrin for a new cancer therapy. Angew Chem Int Ed 36: 1374-1389.
40. Haas TA, Plow EF, (1994) Integrin-ligand interactions: a year in review. Curr Opin Cell Biol 6: 656-662.
41. Cheng Z, De Jesus OP, Kramer DJ, De A, Webster JM, et al. (2010) 64Cu-labeled affibody molecules for imaging of HER2 expressing tumors. Mol Imaging Biol 12: 316-324.
42. Beer AJ, Schwaiger M, (2008) Imaging of integrin αvβ3 expression. Cancer Metastasis Rev 27: 631-644.
43. Schottelius M, Laufer B, Kessler H, Wester HJ, (2009) Ligands for mapping αvβ3-integrin expression in vivo. Acc Chem Res 42: 969-980.
44. Liu S, (2006) Radiolabeled multimeric cyclic RGD peptides as integrin αvβ3 targeted radiotracers for tumor imaging. Mol Pharm 3: 472-487.
45. Liu S, (2009) Radiolabeled cyclic RGD peptides as integrin αvβ3-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjug Chem 20: 2199-2213.
46. Li ZB, Cai W, Cao Q, Chen K, Wu Z, et al. (2007) 64Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor αvβ3 integrin expression. J Nucl Med 48: 1162-1171.
47. Jencks WP, (1981) On the attribution and additivity of binding energies. Proc Natl Acad Sci U S A 78: 4046-4050.
48. Cochran JR, Stern LJ, (2000) A diverse set of oligomeric class II MHC-peptide complexes for probing T-cell receptor interactions. Chem Biol 7: 683-696.
49. Chen X, Park R, Tohme M, Shahinian AH, Bading JR, et al. (2004) MicroPET and autoradiographic imaging of breast cancer αv-integrin expression using 18F- and 64Cu-labeled RGD peptide. Bioconjug Chem 15: 41-49.
50. Chen X, Liu S, Hou Y, Tohme M, Park R, et al. (2004) MicroPET imaging of breast cancer αv-integrin expression with 64Cu-labeled dimeric RGD peptides. Mol Imaging Biol 6: 350-359.
51. Lee S, Xie J, Chen X, (2010) Peptide-based probes for targeted molecular imaging. Biochemistry 49: 1364-1376.
52. Shi J, Kim YS, Zhai S, Liu Z, Chen X, et al. (2009) Improving tumor uptake and pharmacokinetics of 64Cu-labeled cyclic RGD peptide dimers with Gly3 and PEG4 linkers. Bioconjug Chem 20: 750-759.
53. Wu Y, Zhang X, Xiong Z, Cheng Z, Fisher DR, et al. (2005) microPET imaging of glioma integrin αvβ3 expression using 64Cu-labeled tetrameric RGD peptide. J Nucl Med 46: 1707-1718.
54. Zahnd C, Kawe M, Stumpp MT, de Pasquale C, Tamaskovic R, et al. (2010) Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. Cancer Res 70: 1595-1605.
55. Schmidt MM, Wittrup KD, (2009) A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 8: 2861-2871.
56. Cheng Z, De Jesus OP, Namavari M, De A, Levi J, et al. (2008) Small-animal PET imaging of human epidermal growth factor receptor type 2 expression with site-specific 18F-labeled protein scaffold molecules. J Nucl Med 49: 804-813.
57. Tolmachev V, Mume E, Sjoberg S, Frejd FY, Orlova A, (2009) Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. Eur J Nucl Med Mol Imaging 36: 692-701.
58. Swers JS, Kellogg BA, Wittrup KD, (2004) Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display. Nucleic Acids Res 32: e36.
59. Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, et al. (2006) Isolating and engineering human antibodies using yeast surface display. Nat Protoc 1: 755-768.
60. Cheng Z, Wu Y, Xiong Z, Gambhir SS, Chen X, (2005) Near-infrared fluorescent RGD peptides for optical imaging of integrin αvβ3 expression in living mice. Bioconjug Chem 16: 1433-1441.
61. Richards J, Miller M, Abend J, Koide A, Koide S, et al. (2003) Engineered fibronectin type III domain with a RGDWXE sequence binds with enhanced affinity and specificity to human αvβ3 integrin. J Mol Biol 326: 1475-1488.
62. Cai W, Gambhir SS, Chen X, (2005) Multimodality tumor imaging targeting integrin αvβ3. Biotechniques 39: S6-S17.